AVI BioPharma, Inc. (NASDAQ:AVII)

CAPS Rating: 4 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

0
Player Avatar Bojac3728 (< 20) Submitted: 9/1/2009 9:54:05 AM : Outperform Start Price: $2.00 AVII Score: -92.99

Good growthand earnings ahead.

Report this Post Reply

Featured Broker Partners


Advertisement